Incyte posts FY cash provided by operating activities of USD 1.41 billion, up 321%

Reuters05:03

Incyte posts FY cash provided by operating activities of USD 1.41 billion, up 321%

Incyte Corporation reported its financial results for the full year ended December 31, 2025. The company disclosed cash, cash equivalents, and marketable securities totaling USD 3.58 billion as of December 31, 2025, with working capital at USD 3.51 billion. Cash provided by operating activities for the year was USD 1.41 billion. Net interest income for the period was USD 105.6 million, reflecting a decrease due to a lower interest rate environment compared to the previous year. In terms of equity investments, Incyte recorded a gain of USD 11.1 million from its investment in Syndax for the year. Capital expenditures totaled USD 58.9 million. The company highlighted its ongoing global operations, with headquarters in Wilmington, Delaware, and additional commercial and clinical development activities in Europe, Japan, and Canada. No further product or business updates were provided in this earnings release.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000879169-26-000010), on February 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2610676896?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-11 05:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610676896","market":"fut","top_or_hot":-1,"title":"Incyte posts FY cash provided by operating activities of USD 1.41 billion, up 321%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Incyte posts FY cash provided by operating activities of USD 1.41 billion, up 321%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Incyte Corporation reported its financial results for the full year ended December 31, 2025. The company disclosed cash, cash equivalents, and marketable securities totaling USD 3.58 billion as of December 31, 2025, with working capital at USD 3.51 billion. Cash provided by operating activities for the year was USD 1.41 billion. Net interest income for the period was USD 105.6 million, reflecting a decrease due to a lower interest rate environment compared to the previous year. In terms of equity investments, Incyte recorded a gain of USD 11.1 million from its investment in Syndax for the year. Capital expenditures totaled USD 58.9 million. The company highlighted its ongoing global operations, with headquarters in Wilmington, <a href=\"https://laohu8.com/S/VMM\">Delaware</a>, and additional commercial and clinical development activities in Europe, Japan, and Canada. No further product or business updates were provided in this earnings release.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000879169-26-000010), on February 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Incyte posts FY cash provided by operating activities of USD 1.41 billion, up 321%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIncyte posts FY cash provided by operating activities of USD 1.41 billion, up 321%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-11 05:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Incyte posts FY cash provided by operating activities of USD 1.41 billion, up 321%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Incyte Corporation reported its financial results for the full year ended December 31, 2025. The company disclosed cash, cash equivalents, and marketable securities totaling USD 3.58 billion as of December 31, 2025, with working capital at USD 3.51 billion. Cash provided by operating activities for the year was USD 1.41 billion. Net interest income for the period was USD 105.6 million, reflecting a decrease due to a lower interest rate environment compared to the previous year. In terms of equity investments, Incyte recorded a gain of USD 11.1 million from its investment in Syndax for the year. Capital expenditures totaled USD 58.9 million. The company highlighted its ongoing global operations, with headquarters in Wilmington, <a href=\"https://laohu8.com/S/VMM\">Delaware</a>, and additional commercial and clinical development activities in Europe, Japan, and Canada. No further product or business updates were provided in this earnings release.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000879169-26-000010), on February 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INCY","symbol_name":"因塞特医疗","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDL5HQmQX:1","article_id":"2610676896","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610676896","pubTimestamp":1770757385,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Incyte Corporation reported its financial results for the full year ended December 31, 2025. The company disclosed cash, cash equivalents, and marketable securities totaling USD 3.58 billion as of December 31, 2025, with working capital at USD 3.51 billion. Cash provided by operating activities for the year was USD 1.41 billion. Net interest income for the period was USD 105.6 million, reflecting a decrease due to a lower interest rate environment compared to the previous year. In terms of equity investments, Incyte recorded a gain of USD 11.1 million from its investment in Syndax for the year. Capital expenditures totaled USD 58.9 million. The company highlighted its ongoing global operations, with headquarters in Wilmington, Delaware, and additional commercial and clinical development activities in Europe, Japan, and Canada. No further product or business updates were provided in this earnings release.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INCY":"因塞特医疗","BK4532":"文艺复兴科技持仓","BK4139":"生物科技","BK4550":"红杉资本持仓","SNDX":"Syndax Pharmaceuticals, Inc. ","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"Incyte公布财年经营活动提供的现金为14.1亿美元，增长321%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNDX":0.9,"INCY":0.9},"content_text":"Incyte posts FY cash provided by operating activities of USD 1.41 billion, up 321%\n    \n\n        Incyte Corporation reported its financial results for the full year ended December 31, 2025. The company disclosed cash, cash equivalents, and marketable securities totaling USD 3.58 billion as of December 31, 2025, with working capital at USD 3.51 billion. Cash provided by operating activities for the year was USD 1.41 billion. Net interest income for the period was USD 105.6 million, reflecting a decrease due to a lower interest rate environment compared to the previous year. In terms of equity investments, Incyte recorded a gain of USD 11.1 million from its investment in Syndax for the year. Capital expenditures totaled USD 58.9 million. The company highlighted its ongoing global operations, with headquarters in Wilmington, Delaware, and additional commercial and clinical development activities in Europe, Japan, and Canada. No further product or business updates were provided in this earnings release.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000879169-26-000010), on February 10, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2610676896","isCrawlerRequest":true}